搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Burkholderia vietnamiensis ATP-dependent protease ATPase subunit HslU (hslU) CSB-YP392281BPV
CSB-EP392281BPV
CSB-BP392281BPV
CSB-MP392281BPV
CSB-EP392281BPV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia vietnamiensis Aspartyl/glutamyl-tRNA (Asn/Gln) amidotransferase subunit C CSB-YP392282BPV
CSB-EP392282BPV
CSB-BP392282BPV
CSB-MP392282BPV
CSB-EP392282BPV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia vietnamiensis Protease HtpX homolog (htpX), partial CSB-YP392283BPV1
CSB-EP392283BPV1
CSB-BP392283BPV1
CSB-MP392283BPV1
CSB-EP392283BPV1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia vietnamiensis 50S ribosomal protein L34 (rpmH) CSB-YP392284BPV
CSB-EP392284BPV
CSB-BP392284BPV
CSB-MP392284BPV
CSB-EP392284BPV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia vietnamiensis Betaine aldehyde dehydrogenase (betB) CSB-YP392285BPV
CSB-EP392285BPV
CSB-BP392285BPV
CSB-MP392285BPV
CSB-EP392285BPV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia vietnamiensis Putative reductase Bcep1808_3641 (Bcep1808_3641) CSB-YP392286BPV
CSB-EP392286BPV
CSB-BP392286BPV
CSB-MP392286BPV
CSB-EP392286BPV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia vietnamiensis Malate dehydrogenase 1 (mdh1) CSB-YP392287BPV
CSB-EP392287BPV
CSB-BP392287BPV
CSB-MP392287BPV
CSB-EP392287BPV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia vietnamiensis Dihydroxy-acid dehydratase (ilvD), partial CSB-YP392288BPV
CSB-EP392288BPV
CSB-BP392288BPV
CSB-MP392288BPV
CSB-EP392288BPV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia vietnamiensis UPF0345 protein Bcep1808_5077 (Bcep1808_5077) CSB-YP392289BPV
CSB-EP392289BPV
CSB-BP392289BPV
CSB-MP392289BPV
CSB-EP392289BPV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia vietnamiensis 4-hydroxy-2-oxovalerate aldolase 1 (Bcep1808_5384) CSB-YP392290BPV
CSB-EP392290BPV
CSB-BP392290BPV
CSB-MP392290BPV
CSB-EP392290BPV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia vietnamiensis 3- (3-hydroxy-phenyl)propionate/3-hydroxycinnamic acid hydroxylase 2, partial CSB-YP392291BPV
CSB-EP392291BPV
CSB-BP392291BPV
CSB-MP392291BPV
CSB-EP392291BPV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia vietnamiensis Cyanate hydratase (cynS) CSB-YP392292BPV
CSB-EP392292BPV
CSB-BP392292BPV
CSB-MP392292BPV
CSB-EP392292BPV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Influenza A virus Hemagglutinin (HA), partial CSB-YP392293ILO
CSB-EP392293ILO
CSB-BP392293ILO
CSB-MP392293ILO
CSB-EP392293ILO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Influenza A virus Nucleoprotein (NP) CSB-YP392294ILO
CSB-EP392294ILO
CSB-BP392294ILO
CSB-MP392294ILO
CSB-EP392294ILO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Influenza A virus Polymerase acidic protein (PA), partial CSB-YP392295ILO
CSB-EP392295ILO
CSB-BP392295ILO
CSB-MP392295ILO
CSB-EP392295ILO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oryza sativa subsp. indica Ent-isokaur-15-ene synthase (KSL5), partial CSB-YP392296OFF
CSB-EP392296OFF
CSB-BP392296OFF
CSB-MP392296OFF
CSB-EP392296OFF-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rat Killer cell lectin-like receptor subfamily B member 1B allele A (Klrb1b), partial CSB-YP392297RA
CSB-EP392297RA
CSB-BP392297RA
CSB-MP392297RA
CSB-EP392297RA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rat C-type lectin domain family 2 member D3 (Clec2d3), partial CSB-YP392298RA
CSB-EP392298RA
CSB-BP392298RA
CSB-MP392298RA
CSB-EP392298RA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Heliothis virescens ascovirus 3e Putative esterase (ORF19), partial CSB-YP392299HSI
CSB-EP392299HSI
CSB-BP392299HSI
CSB-MP392299HSI
CSB-EP392299HSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Heliothis virescens ascovirus 3e Uncharacterized protein ORF59 (ORF59) CSB-YP392300HSI
CSB-EP392300HSI
CSB-BP392300HSI
CSB-MP392300HSI
CSB-EP392300HSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>